A case of catecholaminergic polymorphic ventricular tachycardia caused by two calsequestrin 2 mutations

PACE - Pacing and Clinical Electrophysiology

Volumn 31, Issue 7, 2008, Pages 916-919

  De La Fuente, Sam ^a   Van Langen, Irene M ^a   Postma, Alex V ^b   Bikker, Henni ^b   Meijer, Albert ^a  

^a CATHARINA HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Calsequestrin 2; Catecholaminergic polymorphic ventricular tachycardia; Clinical; Electrophysiology

Indexed keywords

RYANODINE RECEPTOR 2; CALSEQUESTRIN; CASQ2 PROTEIN, HUMAN; RYANODINE RECEPTOR;

ADULT; ANAMNESIS; ARTICLE; CALSEQUESTRIN 2 GENE; CASE REPORT; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CLINICAL FEATURE; GENE; GENE MUTATION; GENETIC ANALYSIS; HEART RATE; HUMAN; INHERITANCE; MALE; SYNCOPE; GENETIC PREDISPOSITION; GENETICS; HEART VENTRICLE TACHYCARDIA; MUTATION; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CALSEQUESTRIN; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; TACHYCARDIA, VENTRICULAR;

EID: 55249115868     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2008.01111.x     Document Type: Article

References (14)

1. Leenhardt A, Lucet V, Denjoy I, Grau F, Do Ngoc D, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in chil dren. A 7-year follow-up of 21 patients. Circulation 1995; 91:1512-1519.
2. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, et al. Clinical and molecular characterization of pa tients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106:69-74.
3. Krahn AD, Gollob M, Yee R, Gula LJ, Skanes AC, Walker BD, Klein GJ. Diagnosis of unexplained cardiac arrest: Role of adrenaline and procainamide infusion. Circulation 2005; 112:2228-2234.
4. Tan HL, Hofman N, van Langen IM, van der Wal AC, Wilde AAM. Sudden unexplained death: Heritability and diagnostic yield of car- diological and genetic examination in surviving relatives. Circula tion 2005; 112:207-213.
5. Tester DJ, Spoon DB, Valdivia HH, Makielski JC, Ackerman MJ. Tar geted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: A molecular autopsy of 49 medical examiner/coroner's cases. Mayo Clin Proc 2004; 79:1380-1384.
6. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, et al. Mutations in the cardiac ryanodine receptor gene (HRYR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103:196-200.
7. Lahat H, Eldar M, Levy-Nissenbaum E, Bahan T, Friedman E, Khoury A, Lorber A, et al. Autosomal recessive catecholamine- or exercise- induced polymorphic ventricular tachycardia: Clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation 2001; 103:2822-2827.
8. Viatchenko-Karpinski S, Terentyev D, Gyorke I, Terentyeva R, Volpe P, Priori SG, Napolitano C, et al. Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin. Circ Res 2004; 94:471-477.
9. Houle TD, Ram ML, Cala SE. Calsequestrin mutant D307H exhibits depressed binding to its protein targets and a depressed response to calcium. Cardiovasc Res 2004; 64:227-233.
10. Laitinen PJ, Swan H, Kontula K. Molecular genetics of exercise- induced polymorphic ventricular tachycardia: Identification of three novel cardiac ryanodine receptor mutations and two common calsequestrin 2 amino-acid polymorphisms. Eur J Hum Genet 2003; 11:888-891.
11. di Barletta MR, Viatchenko-Karpinski S, Nori A, Memmi M, Teren tyev D, Turcato F, Valleet G, et al. Clinical phenotype and func tional characterization of CASQ2 mutations associated with cat echolaminergic polymorphic ventricular tachycardia. Circulation 2006; 114:1012-1019.
12. Swan H, Piippo K, Viitasalo M, Heikkila PA, Paavonen T, Kainu- lainen K, Kere J, et al. Arrhythmic disorder mapped to chromosome 1q42-Q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 1999; 34:2035-2042.
13. Postma AV, Denjoy I, Kamblock J, Alders M, Lupoglazoff JM, Vaks- mann G, Dubosq-Bidot L, et al. Catecholaminergic polymorphic ven tricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet 2005; 42:863-870.
14. Postma AV, Denjoy I, Hoorntje TM, Lupoglazoff JM, Da Costa A, Sebillon P, Mannens MMAM, et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachy cardia. Circ Res 2002; 91:e21-e26.